31 results
424B5
PRME
Prime Medicine Inc
16 Feb 24
Prospectus supplement for primary offering
6:17am
portfolio include the following:
PM359, our first product candidate within our hematology and immunology area of focus, targets chronic granulomatous
424B5
PRME
Prime Medicine Inc
14 Feb 24
Prospectus supplement for primary offering
5:27pm
hematology and immunology area of focus, targets chronic granulomatous disease, or CGD, a serious life-threatening disease that presents in childhood. PM359
8-K
EX-99.2
PRME
Prime Medicine Inc
7 Aug 23
Prime Medicine Reports Second Quarter 2023 Financial Results and Provides Business Updates
4:04pm
, correct, insert, and delete Performs and corrects insertions, deletions, and all twelve types of single base pair corrections Precisely targets … GGCCCAG-CTGAGCTCGTGA Targeted Sequencing (>1000x) potential off-target editing sites Identified Off-targets Genome wide Nick Detection Assay** Genome
10-Q
1srpk92ct08hwfxcglv
14 Nov 22
Quarterly report
4:46pm
424B4
zk3ys
21 Oct 22
Prospectus supplement with pricing info
4:47pm
S-1/A
q8bs6u jrkqgnujbu
13 Oct 22
IPO registration (amended)
10:51am
S-1
EX-10.14
kqkla
23 Sep 22
IPO registration
4:12pm
S-1
EX-10.13
zos0 5dkvtbm37z
23 Sep 22
IPO registration
4:12pm
S-1
npmeri 7fd3i5ztim
23 Sep 22
IPO registration
4:12pm
S-1
EX-10.4
hj90vdudhmzmvc2
23 Sep 22
IPO registration
4:12pm
DRS/A
l3s9jtw7gkbzlyee3c
5 Aug 22
Draft registration statement (amended)
12:00am
DRS/A
ox15 4laf
6 May 22
Draft registration statement (amended)
12:00am
DRS/A
j8xa1
8 Apr 22
Draft registration statement (amended)
12:00am
DRSLTR
g22y7w
8 Apr 22
Correspondence regarding draft registration statement
12:00am
UPLOAD
32y 24bcdxvo
30 Mar 22
Letter from SEC
12:00am
DRS/A
pu3z4an0jrjg8becme6g
25 Mar 22
Draft registration statement (amended)
12:00am
DRSLTR
eqkprvg00tx8z
25 Mar 22
Correspondence regarding draft registration statement
12:00am